Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07062354 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer

Study acronym: CAPT-HN
StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 8 → 12 locations Eligibility criteria expanded, about 24 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 24 words
  2. Trial sites expanded: 4 → 8 locationsv6
  3. Study sites: 3 to 4v5
  4. Study sites: 2 to 3v4
  5. Trial status changed: Not Yet Recruiting → Enrolling by Invitation Study sites: 0 to 2 · Start date changed from estimate of Feb 2026 to Mar 25, 2026v3 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date changed from estimate of Feb 2026 to Mar 25, 2026
  6. Start date: Dec 2025 to Feb 2026v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research study is for people who have head and neck cancer that has come back or spread to other places in the body.
Trial Details
NCT Number NCT07062354
Lead Sponsor SWOG Cancer Research Network
Collaborators: Janssen Medical Affairs, SWOG Clinical Trials Partnerships, LLC
Conditions Head & Neck Cancer, Head & Neck Squamous Cell Carcinoma
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov